Profile
CYCC VRTX REGN VRNA ARGX ALNY
Company Name Cyclacel Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated Regeneron Pharmaceuticals, Inc. Verona Pharma plc argenx SE Alnylam Pharmaceuticals, Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $10.61M $122.53B $81.42B $72.68B $51.58B $43.35B
Employees 0.01K 6.10K 15.16K 0.21K 1.60K 2.23K
CEO Sing Ee Wong Reshma Kewalramani Leonard S. Schleifer David S. Zaccardelli Timothy Van Hauwermeiren Yvonne L. Greenstreet
Ratings
CYCC VRTX REGN VRNA ARGX ALNY
Quant Rating Score 1 4 4 1 4 3
Quant Rating Strong Sell Buy Buy Strong Sell Buy Neutral
Trading
CYCC VRTX REGN VRNA ARGX ALNY
Last Close $6.365 $434.02 $704.31 $106.91 $929.61 $460.54
High 52 $17.15 $513.76 $788 $106.91 $929.61 $491.09
Low 52 $0.19 $366.54 $482.92 $37.86 $532.27 $224.58
Price vs. 52 Week High -62.89 % -15.52 % -10.62 % 0 % 0 % -6.22 %
Price vs. 52 Week Low 3250 % 18.41 % 45.84 % 182.38 % 74.65 % 105.07 %
Total Return
CYCC VRTX REGN VRNA ARGX ALNY
1 Month Return 0 % 4.13 % 21.84 % 0 % 10.19 % -4.39 %
3 Month Return -15.36 % 11.32 % 22.74 % 1.06 % 40.57 % 0.8 %
6 Month Return 218.25 % -1.06 % 18.51 % 49.92 % 64.35 % 61.42 %
9 Month Return 1718.57 % -6.08 % 3.57 % 66.4 % 45.48 % 84.22 %
YTD Return 1592.82 % 7.78 % -1.13 % 130.21 % 51.16 % 95.72 %
1 Year Return 1603.69 % -3.12 % -5.41 % 180.68 % 61.8 % 96.59 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
CYCC VRTX REGN VRNA ARGX ALNY
Dividend Yield Percentage (TTM) - - 0.45 % - - -
Dividend Paid and Capex Coverage Ration (TTM) -148.61 % 9.76 % 3.92 % -147.93 % 65.28 % 5.97 %
Dividend Per Share (TTM) - - 3.52 % - - -
Payout Ratio (TTM) -0.75 % - 8.22 % - - -
Profitability
CYCC VRTX REGN VRNA ARGX ALNY
Gross Profit Margin TTM 18.52 % 86.28 % 86.27 % 95.15 % 65.82 % 83.99 %
Return on Assets TTM -66.67 % 14.78 % 11.11 % -11.01 % 15.06 % 0.9 %
Return on Equity TTM -187.31 % 21.81 % 14.83 % -30.05 % 18.96 % 26.13 %
Return on Capital Employed TTM -128.19 % 19.59 % 10.3 % -8.31 % 5.04 % 8.03 %
Net Income Per EBT TTM 128.19 % 82.61 % 86.12 % 111.64 % 237.3 % -136.38 %
EBT Per Ebit TTM 46.26 % 111.4 % 146.19 % 130.36 % 147.38 % -12.07 %
EBIT Per Revenue TTM -11324.69 % 34.06 % 24.95 % -25.86 % 13.47 % 8.25 %
Cash Flow To Debt Ratio TTM -121860 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Receivables Turnover TTM 0.11 6.02 2.5 1.93 1.91 3.33
Payables Turnover TTM 0.14 0.4 2.1 2.37 0.9 4.37
Inventory Turnover TTM 0.05 0.99 0.62 0.94 2.26 6.82
Fixed Asset Turnover TTM 56.25 % 388.59 % 280.11 % 6536.22 % 5009.77 % 463.12 %
Asset Turnover TTM 0.99 % 47.15 % 35.36 % 29.27 % 31.97 % 66.16 %
Operating Cash Flow Per Share TTM -8.07 14.55 48.39 -0.85 5.67 2.02
Free Cash Flow Per Share TTM -8.07 13.06 39.66 -0.85 5.58 1.68
Cash Per Share TTM 508.4 % 2459.7 % 8362.68 % 511.43 % 5536.58 % 2072.79 %
Operating Cash Flow Sales Ratio TTM -7522.22 % 31.71 % 34.71 % -43.23 % 17.54 % 8.28 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 89.76 % 81.96 % 100.75 % 98.47 % 83.26 %
Cash Flow Coverage Ratios TTM -121860 % 202.64 % 184 % -29.66 % 932.29 % 9.59 %
Price To Free Cash Flows Ratio TTM -0.35 36.72 19.95 -995.27 129.37 195.85
Price To Operating Cash Flows Ratio TTM -0.14 32.86 16.2 -126.33 146.05 162.25
Price Cash Flow Ratio TTM -0.14 32.86 16.2 -126.33 146.05 162.25
Income Statement (TTM)
CYCC VRTX REGN VRNA ARGX ALNY
Revenue $0B $12B $14.34B $0.03B $2.19B $3.71B
Gross Profit $0B $10.35B $12.24B $0.03B $1.96B $3.04B
Gross Profit Ratio 100% 86.24% 85.35% 93.89% 89.62% 81.77%
EBITDA $-0.01B $4.69B $5.82B $-0.12B $0.11B $0.56B
Net Income $-0.01B $3.95B $4.5B $-0.14B $0.83B $0.31B
EPS Diluted -1.36 15.32 41.48 -1.73 12.78 2.33
Balance Sheet (MRQ)
CYCC VRTX REGN VRNA ARGX ALNY
Long Term Debt $0B $3.69B $2.71B $0.12B $0.03B $2.7B
Total Liabilities $0.01B $6.98B $9.3B $0.27B $0.7B $4.18B
Total Equity $-0B $18.67B $31.26B $0.2B $5.5B $0.79B
Total Investments $0B $5.71B $15.75B $0.02B $1.93B $1.25B
Total Debt $0B $3.69B $2.71B $0.12B $0.04B $2.97B
Total Assets $0B $25.64B $40.56B $0.47B $6.2B $4.97B
Cash Flow Statement (TTM)
CYCC VRTX REGN VRNA ARGX ALNY
Net Income $-0.01B $-0.54B $4.5B $-0.17B $0.83B $0.31B
Inventory $0B $-0.52B $-0.28B $-0.01B $-0.1B $0.01B
Dividends Paid $0B $0B $-0.37B $0B $0B $0B
Operating Cash Flow $-0.01B $-0.49B $4.98B $-0.12B $-0.08B $0.52B
Capital Expenditure $0B $-0.3B $-0.9B $-0B $-0.07B $-0.06B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.05
AAPG 24.6862
AARD Aardvark Therapeutics, Inc. Common Stock 12.045
ABCL AbCellera Biologics Inc. 3.1705
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 5.085
ABIO ARCA biopharma, Inc. 28.8
ABOS Acumen Pharmaceuticals, Inc. 2.615
ABPWW 0.0131
ABSI Absci Corporation 2.605
ABUS Arbutus Biopharma Corporation 4.065
ABVC ABVC BioPharma, Inc. 1.66
ABVX Abivax SA American Depositary Shares 125.66
ACAD ACADIA Pharmaceuticals Inc. 22.0902
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 7.2
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 1.48
ACHV Achieve Life Sciences, Inc. 4.22
ACIU AC Immune SA 3.03
ETFs With Exposure to CYCC
Ticker ETF Name Weight Percentage Price
ITOT iShares Core S&P Total U.S. Stock Market ETF 0 149.895
VXF Vanguard Extended Market Index Fund 0 217.075
VIEIX Vanguard Extended Market Index Fund Institutional Shares 0 162.32
VEXAX Vanguard Extended Market Index Fd Admiral Shs 0 162.33
VEMPX Vanguard Extended Market Index InstlPlus 0 400.57
Unlock